JRJeremy L. Rempel

Jeremy L. Rempel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeremy L. Rempel has a total of 343 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Improvement, No Improvement, and Worsening at 24 Hours Following Reperfusion in Patients With Stroke due to Large-Vessel Occlusion

    by Umberto Pensato, Thalia S. Field, Brian van Adel, Ruchir Shah, Jason W. Tarpley, Hana Choe, Nima Kashani, Mohammed Almekhlafi, Raul G. Nogueira, Ryan A. McTaggart, et al.

    BACKGROUND: Restoring blood flow to ischemic tissue is the cornerstone of acute stroke therapy and is usually beneficial. However, when reperfusion is achieved for severely injured tissue, it is often futile and may occasionally cause harm. We aim to determine the prevalence and variables associated with clinical no improvement or acute worsening at 24 hours despite reperfusion in patients with large-vessel occlusion stroke treated with endovascular thrombectomy. METHODS: Data are from ESCAPE-NA1 (Safety and Efficacy of Nerinetide [NA-1] in Subjects Undergoing Endovascular Thrombectomy for Stroke), a randomized trial of nerinetide in patients with acute large-vessel occlusion stroke undergoing endovascular thrombectomy. Patients with unsuccessful recanalization (expanded Thrombolysis in Cerebral Infarction <2b), infarcts in new vascular territories, vessel perforation, or remote parenchymal hemorrhage were excluded. Clinical outcomes after reperfusion were classified by 24-hour National Institutes of Health Stroke Scale changes compared with baseline: improvement (≥4-point improvement), no improvement (±3-point from baseline), and worsening (≥4-point worsening). Baseline variables associated with worsening were identified using logistic regression. In the computed tomography perfusion subgroup, prevalence of parenchymal hemorrhage (any parenchymal hematoma) and infarct progression (final infarct volume exceeding the initial hypoperfused region) were evaluated. RESULTS: A total of 833 patients were included (median age, 70.9 years [interquartile range, 60.7–79.4]; 51.4% men). After reperfusion, 669 (80.3%) patients improved, 135 (16.2%) showed no improvement, and 29 (3.5%) worsened. Independent predictors of worsening were longer onset-to-reperfusion time (adjusted odds ratio, 1.02 [95% CI, 1.00–1.04] per 10-minute increase) and greater degree of sedation (adjusted odds ratio, 1.78 [95% CI, 1.29–2.46] per category of none, conscious sedation, and general anesthesia). In the computed tomography perfusion subgroup (n=414), among patients with worsening after reperfusion, parenchymal hemorrhage was seen in 5 patients (31.3%) and infarct progression in 4 patients (25%). CONCLUSIONS: Clinical worsening in the acute period (ie, early neurological deterioration) despite reperfusion and the absence of procedure-related complications was rare in this selected large-vessel occlusion stroke cohort (3.5%). Factors associated with worsening after reperfusion were a longer time from symptom onset-to-reperfusion and a higher degree of sedation.

  • Visualization of the Human Intracranial Vasculature and Intracranial Implants Using Microangioscopy

    by Robert Fahed, Visish M. Srinivasan, Cian O’KElly, Francois Belzile, Khaled Effendi, Jeremy Rempel, William Siu, Zoe Tsai, Nicole Cancelliere, Pascal J. Mosimann, et al.

    BACKGROUND: Cerebral angiography cannot directly assess the intimal surface of a vessel. The MicroAngioscope is a small and flexible catheter that allows visualization of the inside of the cerebral vasculature. Our objective is to report our first-in-human experience with the live visualization of intracranial vasculature using the MicroAngioscope. METHODS: This was a prospective, single-arm, national multi-center observational study of consecutive intracranial endovascular cases treated using the MicroAngioscope as an adjunct. This first-in-human study aimed at assessing the safety of the technology by prospectively collecting any procedural complications. A secondary end point was the successful visualization of the vasculature and the implants. RESULTS: The MicroAngioscope, used in 31 cases, was successfully delivered to the location of interest and allowed for a direct live visualization of the condition and the implant that had been deployed. There was no vessel injury based on cerebral angiography. The cases included 9 cases of carotid stent, 6 cases of flow diversion, 11 cases of transverse sinus stenting, 2 cases of aneurysm intrasaccular flow-disruption, 1 case of aneurysm treatment with stent-assisted coiling, and 2 cases of mechanical thrombectomy. All cases were successfully completed without complications. All patients were neurologically unchanged following their respective procedures. Angioscopy was helpful in making the diagnosis in the case of the carotid web, assessing vessel wall apposition immediately after flow diverter and venous stent deployment, and assessing the degree of strut coverage in both arterial and venous stents in follow-up. CONCLUSIONS: This First-in-Human study demonstrated the early feasibility and safety of the MicroAngioscope in neurointerventional procedures. Further studies are needed to determine its relevance in daily practice.


  • Open Access

    Province of Alberta Jurisdictional Standardized Operating Protocol (SOP) for Screening Brain Vascular Malformations

    by Ryan Alexander Spychka, Michael D. Hill, Jeremy Rempel, Sandeep Naik, Richard Owen, Oliver Halliwell, Thomas Jeerakathil, Karim Samji, Dilini Vethanayagam

    Objective: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant genetic disorder leading to vascular malformations in different organ systems. Approximately 10% of patients with HHT have brain vascular malformations (BVMs). Due to the negative health consequences related to BVMs, screening with MRI is recommended. There are no health jurisdictional standards for medical imaging protocols in North America or elsewhere. The objective of this project is to adopt a provincial standardized operating protocol (SOP) to improve diagnostic accuracy and reduce inappropriate imaging in patients with and without HHT in Alberta. Methods: Multiple fora were held among the five Alberta Health Services zones with stakeholders from urban, suburban and rural radiology groups, neurology, pulmonology and hematology. The consensus process took five years to complete between 2015 and 2020. The content of the fora was approved by all participants. Results: The SOP was implemented in February 2020 and defines that screening for BVMs must include standard unenhanced brain MRI (sagittal T1, axial fluid-attenuated inversion recovery and axial T2) with susceptibility-weighted imaging (SWI), a 3T or 1.5T magnet strength and minimum imaging standards to include 3 mm contiguous slice thickness. Discussion: Incorporation of SWI allowed for the elimination of MR contrast to improve access to the local performance of studies within the province, facilitating virtual care. Conclusion: A provincial SOP for BVM screening in patients with suspected or confirmed HHT was successfully implemented in Alberta. Gadolinium was avoided, as it was felt to be unnecessary for screening purposes and might complicate imaging at more remote sites.

  • Top Cited Papers

    Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion

    by Mayank Goyal, Johanna M Ospel, Aravind Ganesh, Dar Dowlatshahi, David Volders, Markus A Möhlenbruch, Mouhammad A Jumaa, Shahid M Nimjee, Thomas C Booth, Brian H Buck, et al.

    Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective, randomized, open-label trial with blinded outcome evaluation, we assigned patients with acute ischemic stroke due to medium-vessel occlusion who presented within 12 hours from the time that they were last known to be well and who had favorable baseline noninvasive brain imaging to receive EVT plus usual care or usual care alone. The primary outcome was the modified Rankin scale score (range, 0 [no symptoms] to 6 [death]) at 90 days, reported as the percentage of patients with a score of 0 or 1. A total of 530 patients from five countries were enrolled between April 2022 and June 2024, with 255 patients assigned to the EVT group and 275 to the usual-care group. Most patients (84.7%) had primary occlusions in a middle-cerebral-artery branch. A modified Rankin scale score of 0 or 1 at 90 days occurred in 106 of 255 patients (41.6%) in the EVT group and in 118 of 274 (43.1%) in the usual-care group (adjusted rate ratio, 0.95; 95% confidence interval [CI], 0.79 to 1.15; P = 0.61). Mortality at 90 days was 13.3% in the EVT group and 8.4% in the usual-care group (adjusted hazard ratio, 1.82; 95% CI, 1.06 to 3.12). Symptomatic intracranial hemorrhage occurred in 14 of 257 patients (5.4%) in the EVT group and in 6 of 272 (2.2%) in the usual-care group. Endovascular treatment for acute ischemic stroke due to medium-vessel occlusion within 12 hours did not lead to better outcomes at 90 days than usual care. (Funded by the Canadian Institutes for Health Research and Medtronic; ESCAPE-MeVO ClinicalTrials.gov number, NCT05151172.).


  • Association of baseline infarct size, reperfusion grade and intracranial hemorrhage in patients undergoing thrombectomy

    by Alexander Stebner, Salome Lou Bosshart, Satoru Fujiwara, Donald Frei, Jason Tarpley, Dariush Dowlatshahi, Jeremy L Rempel, Michael D Hill, Mayank Goyal, Johanna M Ospel

    Background Better reperfusion status results in smaller infarct volumes and better outcomes after thrombectomy. However, if large tissue volumes are already infarcted at baseline, reperfusion might also increase the risk of intracranial hemorrhage. This study aims to investigate the interaction between reperfusion status, baseline ischemic changes, and intracranial hemorrhage following thrombectomy. Methods Retrospective analysis of the ESCAPE-NA1 randomized trial. Unadjusted and adjusted logistic regression models were used to estimate the associations of Alberta Stroke Program Early CT Score (ASPECTS) and expanded Treatment In Cerebral Infarction (eTICI) score on post-treatment hemorrhage. Treatment effect modification was assessed by including multiplicative interaction terms (ASPECTS*eTICI) in these models. Results A total of 1077 patients were included. Median age was 70.8 (IQR 60.7–79.7) and 543 (50.4%) were female. Any intracranial hemorrhage on 24-hour follow-up imaging occurred in 368/1077 (34.2%) patients. There was evidence of modification of the effect of final angiogram eTICI score on any intracranial hemorrhage by baseline ASPECTS (P=0.008). Marginal probabilities showed increased hemorrhage risk for patients with low ASPECTS with increasing final eTICI scores. This association was reversed in patients with small baseline ischemic changes and successful reperfusion. There was no association with symptomatic intracranial hemorrhage or parenchymal hematoma. Conclusion The association of post-thrombectomy reperfusion status and post-treatment hemorrhage may be modified by the extent of baseline ischemia. Reperfusion is associated with reduced risk of hemorrhage in patients with small baseline infarcts, but increased hemorrhage risk in patients with extensive ischemic changes at baseline. However, no significant association was found with symptomatic intracranial hemorrhage or parenchymal hematoma. Trial registration number NCT02930018.


  • Factors Influencing Nerinetide Effect on Infarct Volume in Patients Without Alteplase in the Randomized ESCAPE-NA1 Trial

    by Johanna M. Ospel, Mayank Goyal, Bijoy K. Menon, Mohammed A. Almekhlafi, Charlotte Zerna, Raul G. Nogueira, Ryan A. McTaggart, Andrew M. Demchuk, Alexandre Y. Poppe, Jeremy L. Rempel, et al.

    BACKGROUND: In the ESCAPE-NA1 trial (Efficacy and Safety of Nerinetide for the Treatment of Acute Ischemic Stroke), treatment with nerinetide was associated with a smaller infarct volume among patients who did not receive intravenous alteplase. We assessed the effect of nerinetide on the surrogate imaging outcome of final infarct volume in patients who did not receive intravenous alteplase and explored predictors of outcome and modifiers of nerinetide’s effect on infarct volume. METHODS: ESCAPE-NA1 was a multicenter, randomized trial in which patients with acute stroke with a baseline Alberta Stroke Program Early CT Score >4, undergoing endovascular thrombectomy, were randomized to receive intravenous nerinetide or placebo. Patients not receiving intravenous alteplase were included in this post hoc secondary analysis of the trial data. Final infarct volume was manually segmented on 24-hour noncontrast computed tomography or diffusion-weighted magnetic resonance imaging. Predictors of final infarct volume were identified using multivariable linear regression with cubic-root-transformed infarct volume as the dependent variable. Evidence of treatment-by-predictor interaction was tested by including interaction terms in the model. RESULTS: Four hundred forty-six patients (219 who received nerinetide and 227 who received a placebo) out of a total of 1105 enrolled patients were included in this secondary post hoc analysis of the randomized ESCAPE-NA1 trial. Nerinetide was a strong predictor of smaller infarct volume (adjusted β coefficient, −0.35 [95% CI, −0.67 to −0.02]). Other predictors of smaller infarct volume were history of hypertension, good pial collateral filling on multiphase computed tomography angiography, a middle cerebral artery occlusion compared with an internal carotid artery occlusion, lower baseline National Institutes of Health Stroke Scale score, lower baseline systolic blood pressure, lower baseline serum glucose, shorter onset-to-randomization time, and higher Alberta Stroke Program Early CT Score. There was evidence of a treatment-by-systolic blood pressure and treatment-by-anesthesia interaction: nerinetide attenuated the negative effects of elevated baseline ( P interaction =0.02) and postdose ( P interaction =0.04) systolic blood pressure and use of general anesthesia ( P interaction =0.06) on final infarct volume. We observed a marginally significant interaction with reperfusion status, such that nerinetide may attenuate the harmful effect of poor reperfusion status on infarct volume ( P interaction =0.08). CONCLUSIONS: Nerinetide treatment was strongly associated with smaller final infarct volumes among patients not cotreated with alteplase. The reduction in infarct volume was greater among patients with poor prognostic factors. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02930018.


  • Flow Diversion for the Treatment of Distal Circulation Aneurysms: A Randomized Comparison

    by William Boisseau, Tim E. Darsaut, Robert Fahed, Brian Drake, Howard Lesiuk, Jeremy L. Rempel, Cian J. O’kelly, Michael M.C. Chow, Daniela Iancu, Daniel Roy, et al.

    BACKGROUND AND PURPOSE: Flow diversion (FD) has expanded beyond initial indications (proximal carotid artery aneurysms) to include distal circulation aneurysms (on the anterior, middle, or posterior cerebral arteries). Our objective was to examine results obtained from aneurysms in these locations in the Flow Diversion in the Treatment of Intracranial Aneurysms Trial (FIAT) which compared FD with alternative standard management options (ASMO). MATERIALS AND METHODS: FIAT was an all-inclusive parallel-group 1:1 randomized study comparing FD with one of 4 ASMOs (coiling +/-stenting, parent vessel occlusion (PVO), clipping, or observation, pre-specified by clinical judgment). The primary safety outcome was death or dependency (mRS >2) at 3 months. The composite primary outcome was “treatment failure,” defined as initial failure to treat the aneurysm; aneurysm rupture or retreatment during follow-up; death or dependency (mRS>2); or angiographic residual aneurysm adjudicated by independent core laboratory at 12 months. This subgroup analysis was not prespecified and there was no blinding. RESULTS: Of the 323 patients in FIAT, 46 (14%) with distal circulation aneurysms were randomly allocated: 23 to FD and 23 to ASMO (coiling +/-stenting (16 patients), PVO (1), clipping (3), and observation (3)). Death or dependency at 3 months occurred in one patient (allocated ASMO). Treatment failures occurred in 6/23 FD-treated patients (26.1%; 95%CI: 12.6%-46.5%) compared to 11/22 patients treated with ASMO (50.0%; 95%CI: 30.7%-69.3%; RR=0.52, [0.23-1.17]; P=0.13). Serious adverse events were similar. CONCLUSIONS: Distal circulation aneurysms treated with FDs in FIAT showed an encouraging trend, but this analysis was underpowered. Further randomized trials are needed. ABBREVIATIONS: ASMO = Alternative standard management options; FD = Flow Diversion; FIAT = Flow Diversion in the Treatment of Intracranial Aneurysms Trial; PVO = Parent Vessel Occlusion; mRS = modified Rankin Scale


  • Open Access

    Endovascular Parent Vessel Occlusion Versus Flow Diversion in the Treatment of Large and Giant Aneurysms: A Randomized Comparison

    by William Boisseau, Tim E. Darsaut, Robert Fahed, Pierre Olivier Comby, Brian Drake, Howard Lesiuk, Jeremy L. Rempel, Cian J. O'KElly, Michael M.C. Chow, Daniela E. Iancu, et al.


  • Open Access

    Prevalence of “Ghost Infarct Core” after Endovascular Thrombectomy

    by Johanna M. Ospel, Nathaniel Rex, Leon Rinkel, Nima Kashani, Brian Buck, Jeremy Rempel, Demetrios Sahlas, Michael E. Kelly, Ron Budzik, Michael Tymianski, et al.

    BACKGROUND AND PURPOSE: Baseline CTP sometimes overestimates the size of the infarct core (“ghost core” phenomenon). We investigated how often CTP overestimates infarct core compared with 24-hour imaging, and aimed to characterize the patient subgroup in whom a ghost core is most likely to occur. MATERIALS AND METHODS: Data are from the randomized controlled ESCAPE-NA1 trial, in which patients with acute ischemic stroke undergoing endovascular treatment were randomized to intravenous nerinetide or placebo. Patients with available baseline CTP and 24-hour follow-up imaging were included in the analysis. Ghost infarct core was defined as CTP core volume minus 24-hour infarct volume > 10 mL). Clinical characteristics of patients with versus without ghost core were compared. Associations of ghost core and clinical characteristics were assessed by using multivariable logistic regression. RESULTS: A total of 421 of 1105 patients (38.1%) were included in the analysis. Forty-seven (11.2%) had a ghost core > 10 mL, with a median ghost infarct volume of 13.4 mL (interquartile range 7.6–26.8). Young patient age, complete recanalization, short last known well to CT times, and possibly male sex were associated with ghost infarct core. CONCLUSIONS: CTP ghost core occurred in ∼1 of 10 patients, indicating that CTP frequently overestimates the infarct core size at baseline, particularly in young patients with complete recanalization and short ischemia duration.


  • Open Access

    Infarcts in a New Territory: Insights From the ESCAPE-NA1 Trial

    by Nishita Singh, Petra Cimflova, Johanna Maria Ospel, Nima Kashani, Martha Marko, Arnuv Mayank, Raul G. Nogueira, Ryan A. McTaggart, Andrew M. Demchuk, Alexandre Y. Poppe, et al.

    Background: Infarct in a new territory (INT) is a known complication of endovascular stroke therapy. We assessed the incidence of INT, outcomes after INT, and the impact of concurrent treatments with intravenous thrombolysis and nerinetide. Methods: Data are from ESCAPE-NA1 trial (Safety and Efficacy of Nerinetide [NA-1] in Subjects Undergoing Endovascular Thrombectomy for Stroke), a multicenter, international randomized study that assessed the efficacy of intravenous nerinetide in subjects with acute ischemic stroke who underwent endovascular thrombectomy within 12 hours from onset. Concurrent treatment and outcomes were collected as part of the trial protocol. INTs were identified on core lab imaging review of follow-up brain imaging and defined by the presence of infarct in a new vascular territory, outside the baseline target occlusion(s) on follow-up brain imaging (computed tomography or magnetic resonance imaging). INTs were classified by maximum diameter (20 mm), number, and location. The association between INT and clinical outcomes (modified Rankin Scale and death) was assessed using standard descriptive techniques and adjusted estimates of effect were derived from Poisson regression models. Results: Among 1092 patients, 103 had INT (9.3%, median age 69.5 years, 49.5% females). There were no differences in baseline characteristics between those with versus without INT. Most INTs (91/103, 88.3%) were not associated with visible occlusions on angiography and 39 out of 103 (37.8%) were >20 mm in maximal diameter. The most common INT territory was the anterior cerebral artery (27.8%). Almost half of the INTs were multiple (46 subjects, 43.5%, range, 2–12). INT was associated with poorer outcomes as compared to no INT on the primary outcome of modified Rankin Scale score of 0 to 2 at 90 days (adjusted risk ratio, 0.71 [95% CI, 0.57–0.89]). Infarct volume in those with INT was greater by a median of 21 cc compared with those without, and there was a greater risk of death as compared to patients with no INT (adjusted risk ratio, 2.15 [95% CI, 1.48–3.13]). Conclusions: Infarcts in a new territory are common in individuals undergoing endovascular thrombectomy for acute ischemic stroke and are associated with poorer outcomes. Optimal therapeutic approaches, including technical strategies, to reduce INT represent a new target for incremental quality improvement of endovascular thrombectomy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02930018.